Research graph
References from Dupilumab Targeting IL ‐4/ IL ‐13 Pathway Improves RTK ‐ and PD ‐1‐Inhibitor‐Related Cutaneous Adverse Drug Reactions. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/j.jdcr.2021.07.001
10.1016/j.jdcr.2021.07.001 · External reference
10.1016/j.ctrv.2019.05.004
10.1016/j.ctrv.2019.05.004 · External reference
10.1016/j.jaad.2025.08.008
10.1016/j.jaad.2025.08.008 · External reference
10.1016/j.jdcr.2025.06.027
10.1016/j.jdcr.2025.06.027 · External reference
10.1186/s12885‐025‐14092‐1
10.1186/s12885‐025‐14092‐1 · External reference
